Pliant Therapeutics Ownership
| PLRX Stock | USD 1.55 0.03 1.90% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 61 M | Current Value 61 M | Avarage Shares Outstanding 35.8 M | Quarterly Volatility 22.1 M |
Pliant |
Pliant Stock Ownership Analysis
About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.31. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pliant Therapeutics recorded a loss per share of 3.47. The entity had not issued any dividends in recent years. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. To find out more about Pliant Therapeutics contact MBA MD at 650 481 6770 or learn more at https://pliantrx.com.Besides selling stocks to institutional investors, Pliant Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pliant Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pliant Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pliant Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Pliant Therapeutics are currently held by insiders. Unlike Pliant Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pliant Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pliant Therapeutics' insider trades
Pliant Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pliant Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pliant Therapeutics backward and forwards among themselves. Pliant Therapeutics' institutional investor refers to the entity that pools money to purchase Pliant Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | First Light Asset Management, Llc | 2024-12-31 | 1.7 M | State Street Corp | 2024-12-31 | 1.4 M | Geode Capital Management, Llc | 2024-12-31 | 1.3 M | Silverarc Capital Management, Llc | 2024-12-31 | 1.3 M | Ra Capital Management, Llc | 2024-12-31 | 1.3 M | Pictet Asset Manangement Sa | 2024-12-31 | 1.3 M | Great Point Partners Llc | 2024-12-31 | 1.1 M | Franklin Resources Inc | 2024-12-31 | 1 M | Candriam Luxembourg S.c.a. | 2024-12-31 | 900.1 K | Deep Track Capital, Lp | 2024-12-31 | 6 M | Blackrock Inc | 2024-12-31 | 5.2 M |
Pliant Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pliant Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pliant Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pliant Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pliant Therapeutics Outstanding Bonds
Pliant Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pliant Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pliant bonds can be classified according to their maturity, which is the date when Pliant Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.